Riskpilot← Back to searchSign inGet full accessNK KLINIKKER AS
ASActiveOrg 892445982Bygdøy Allé 51A, 0265 OsloOther human health activities n.e.c. · NACE 8699Est. 20080 employeeswww.novelaklinikken.no
Revenue 2024
NOK 0
EBITDA margin
—
-41% vs 2023
Equity ratio
7.2%
Financial strength
Net profit 2024
NOK 61K
+335% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -40K | -41% |
| Net profit | NOK 61K | +335% |
| Total assets | NOK 39,3M | -2% |
| Equity | NOK 2,8M | -21% |
| Employees | 0 | — |
Legal name
NK KLINIKKER AS
Org number
892445982
Legal form
Aksjeselskap
NACE code
8699 · Other human health activities n.e.c.
Founded
7. april 2008
Share capital
NOK 130 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Medisinske behandlinger, skjønnhetspleie, salg av produkter og andre produkter/tjenester som naturlig hører sammen med dette.
Address
Bygdøy Allé 51A, 0265 Oslo
Website
www.novelaklinikken.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −21 | −19 | −7 | −29 | −40 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −21 | −19 | −7 | −29 | −40 |
| Net financials | 2 683 | −800 | 800 | 47 | 122 |
| Profit before tax | 2 662 | −819 | 793 | 18 | 82 |
| Tax | 543 | −4 | −1 | 4 | 20 |
| Net profit | 2 119 | −815 | 795 | 14 | 61 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 39 979 | 38 967 | 40 056 | 40 070 | 39 332 |
| Equity | 3 578 | 2 763 | 3 558 | 3 572 | 2 833 |
| Long-term debt | 36 401 | 36 200 | 36 194 | 36 194 | 36 194 |
| Short-term debt | 0 | 4 | 304 | 304 | 304 |
| Total debt | 36 401 | 36 204 | 36 498 | 36 498 | 36 498 |
EBITDA margin
-4021600.0%
This company
15.8%
Market median
-25453265% vs market
20202024
Equity ratio
7.2%
This company
38.2%
Market median
-81% vs market
20202024
Return on equity
2.2%
This company
18.4%
Market median
-88% vs market
20202024
Net profit margin
6141400.0%
This company
8.1%
Market median
+75819653% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
12.88×
This company
0.62×
Market median
-1977% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
FR Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (2) | ||
FR Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
FS Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 91% | 91% | 2022 | |
| Company | 9% | 9% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Midgard Eiendom As
NK KLINIKKER AS Board members of NK KLINIKKER AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Frode Røste | Chief Executive Officer | 0 companies |
| Frode Røste Solvang | Chief Executive Officer | 0 companies |
| Frode Solvang | Chief Executive Officer | 0 companies |
| Nikolai Paus Grova | Chairman | 0 companies |